Rapamycin for Longevity: Why the PEARL Trial Isn't What Podcasters Claim

The PEARL rapamycin trial is the longest human study of this longevity drug ever published — but the headlines are misleading. In this video, we break down exactly what PEARL showed, what it didn't, and what it means for you. We cover: what rapamycin is and how it inhibits mTOR, how the 48-week PEARL trial was designed, why the primary endpoint (visceral fat) actually failed, the eye-catching 5% lean mass gain and pain reduction in post-menopausal women on 10mg weekly, why that result came from just 8 participants, the safety profile at intermittent low doses, and the real risks — teratogenicity, immunosuppression, drug interactions, and lipid changes. We also discuss the conflicts of interest with AgelessRx and compounded rapamycin from telehealth clinics. If you're curious about longevity science, mTOR inhibitors, or biohacking with rapamycin, this is the honest, evidence-based breakdown you need before talking to a doctor — or a telehealth clinic. Resistance training, protein, and sleep still outperform most pharmacology for lean mass and healthspan. If this helped you think more clearly about longevity research, hit like, subscribe for more science-first health breakdowns, and let me know in the comments: would you try weekly rapamycin?